Usana Health Sciences Azioni (NYSE: USNA)

Ultime notizie per Usana Health Sciences (NYSE:USNA) Azioni

USANA HEALTH SCIENCES INC

Usana Health Sciences

Usana Health Sciences Inc is a direct selling and direct-to-consumer nutrition, personal health and wellness company. It developed and manufactured science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness. The company has two reportable segments: direct selling and Hiya direct-to-consumer. The direct selling segment develops and manufactures high quality, science-based nutritional, personal care and skincare products with a focus on promoting long-term health and wellness in various geographic markets that are distributed through the direct selling channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the U.S. Key revenue is generated from Direct selling segment.

Usana Health Sciences Inc

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $36.

News

Price Target

Analyst Ratings

USNA

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $36

WIIM

Usana Health Sciences shares are trading higher after the company reported better-than-expected Q4 financial results.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is looking for FY2025 GAAP EPS of $1.50-$2.20 vs $2.73 analyst estimate..

Guidance

Usana Health Sciences Sees FY2025 GAAP EPS $1.50-$2.20 vs $2.73 Est

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is looking for FY2025 Adj EPS of $2.35-$3.00 vs $2.73 analyst estimate. sees sales of $920.000 million-$1.000 billion vs $934.51 million analyst estimate.

Usana Health Sciences Sees FY2025 Adj EPS $2.35-$3.00 vs $2.73 Est; Sees Sales $920.000M-$1.000B vs $934.51M Est

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.49 by 30.61 percent. This is a 26.44 percent decrease over earnings of $0.87 per share from the same period last year. The company reported quarterly sales of $213.61 million which beat the analyst consensus estimate of $208.84 million by 2.28 percent. This is a 3.38 percent decrease over sales of $221.08 million the same period last year.

Earnings

Earnings Beats

Usana Health Sciences Q4 Adj $0.64 Beats $0.49 Estimate, Sales $213.61M Beat $208.84M Estimate

AHCO

ALLT

ARQT

AXGN

AXON

BASE

BGFV

BLZE

BTDR

BWIN

CART

CAVA

CBLL

CCCS

CECO

CGBD

CHRD

CIFR

CPNG

CPSS

DAWN

DNUT

DOCN

DRVN

ELAN

EXLS

FIHL

FLYW

FSLR

FULC

GPOR

HRMY

HSIC

HURN

HYLN

IART

ICCC

IGIC

IMOS

INGN

INTU

INVX

IPAR

ITRI

IVAC

JACK

JAZZ

KEYS

KNSA

LCID

LGIH

LIVN

LMND

LXFR

MASI

MATX

MFIC

MIDD

MMSI

MPLN

MRVI

NOVT

NXRT

Earnings Scheduled For February 25, 2025

USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.&nbsp; Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.
&nbsp;

USANA Names Dr. Kathryn Armstrong As New Chief Scientific Officer

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and raises the price target from $35 to $38.

DA Davidson Maintains Neutral on Usana Health Sciences, Raises Price Target to $38

USANA Acquires 78.8% Stake In Hiya Health For $205M, Expanding Into Direct-To-Consumer Children's Wellness Market; Deal Expected To Add $103M In Sales And Boost 2025 Adjusted EBITDA Immediately

USANA Health Sciences shares are trading higher following mixed Q3 financial results.

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $38 to $35.

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $35

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.56 per share which beat the analyst consensus estimate of $0.48 by 16.67 percent. This is a 5.08 percent decrease over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $200.22 million which missed the analyst consensus estimate of $205.77 million by 2.70 percent. This is a 6.16 percent decrease over sales of $213.37 million the same period last year.

Earnings Misses

Usana Health Sciences Q3 EPS $0.56 Beats $0.48 Estimate, Sales $200.22M Miss $205.77M Estimate

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) narrows FY2024 GAAP EPS guidance from $2.40-2.55 to $2.45 vs $2.50 analyst estimate. Narrows FY2024 sales outlook from $850.00 million-880.00 million to $850.00 million vs $861.94 million estimate.

Usana Health Sciences Narrows FY2024 GAAP EPS Guidance from $2.40-2.55 to $2.45 vs $2.50 Est; Narrows FY2024 Sales Guidance from $850.00M-880.00M to $850.00M vs $861.94M Est.

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-22. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Usana Health Sciences to report an earnings per share (EPS) of $0.48.
Investors in Usana Health Sciences are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company missed EPS by $0.11, leading to a 3.2% drop in the share price the following trading session.
Here's a look at Usana Health Sciences's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.65</td>
<td>0.69</td>
<td>0.52</td>
<td>0.64</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.54</td>
<td>0.86</td>
<td>0.87</td>
<td>0.59</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>10.0%</td>
<td>4.0%</td>
<td>-18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729530097_0.png" alt="eps graph" />
<h3>Usana Health Sciences Share Price Analysis</h3>
Shares of Usana Health Sciences were trading at $35.85 as of October 18. Over the last 52-week period, shares are down 37.0%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/USNA/earnings">To track all earnings releases for Usana Health Sciences visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights Ahead: Usana Health Sciences's Quarterly Earnings

Xencor (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xncr#NASDAQ">XNCR</a>) shares rallied 10.5% in the last trading session to close at $21.13. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock&#39;s 19.8% gain over the past four weeks.
This jump in share price came after the company announced that it was floating a secondary issue of common stock, along with pre-funded warrants, to raise nearly $175 million in gross proceeds. Management intends to issue more than 6.6 million shares at $18 apiece, along with pre-funded warrants to buy an additional 3 million shares for $17.99 a warrant.
Xencor will likely use these funds to support its pipeline development. Last week, the company unveiled details on four new programs targeting autoimmune diseases.
This biotech developing antibodies for severe autoimmune/allergic diseases and cancer is expected to post quarterly loss of $1.01 per share in its upcoming report, which represents a year-over-year change of -152.5%. Revenues are expected to be $7.74 million, down 86.9% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Xencor, the consensus EPS estimate for the quarter has been revised 0.8% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn&#39;t usually translate into price appreciation. So, make sure to keep an eye on XNCR going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold).
Xencor belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, USANA Health Sciences (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/usna#NYSE">USNA</a>), closed the last trading session 0.2% lower at $37.28. Over the past month, USNA has returned -3%.
For USANA Health, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.49. This represents a change of -17% from what the company reported a year ago. USANA Health currently has a Zacks Rank of #4 (Sell).
<a href="https://www.zacks.com/stock/news/2334996/xencor-xncr-surges-10-5-is-this-an-indication-of-further-gains?cid=CS-BENZ-FT-tale_of_the_tape|daily_price_change_5%-2334996">To read this article on Zacks.com click here.</a>

Biotech

Small Cap

Management

Markets

Trading Ideas

General

XNCR

Xencor Surges 10.5%: Is This an Indication of Further Gains?

DA Davidson analyst Linda Bolton Weiser maintains Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) with a Neutral and lowers the price target from $46 to $38.

DA Davidson Maintains Neutral on Usana Health Sciences, Lowers Price Target to $38

Usana Health Sciences shares are trading lower after the company reported worse-than-expected Q2 financial results.

USANA Health Sciences Updates FY24 Net Sales Outlook From $850M - $920M To $850M - $880M (Est $883.518M) And EPS Outlook From $2.40 - $3.00 To $2.40 - $2.55 (Est $2.78)

Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.65 by 16.92 percent. The company reported quarterly sales of $212.869 million which missed the analyst consensus estimate of $221.032 million by 3.69 percent. This is a 10.64 percent decrease over sales of $238.202 million the same period last year.

Usana Health Sciences Q2 2024 GAAP EPS $0.54 Misses $0.65 Estimate, Sales $212.869M Miss $221.032M Estimate

Press Releases

USANA Kids Eat Celebrates 5 Years Making a Difference in Utah with Holiday Donation Drive

USANA Health Sciences Announces Strategic Acquisition of Hiya Health

Kevin Guest Calls for Prioritizing Quality of Life During International Quality of Life Month

USANA Health Sciences to Participate in the 27th Annual ICR Conference

USANA Schedules Fourth Quarter and Fiscal Year 2024 Earnings Release and Conference Call

USANA Appoints New Chief Scientific Officer

Kevin Guest Encourages Confidence, Personal Growth for International Boost Self-Esteem Month

USANA Health Sciences Reports Fourth Quarter and Full Year 2024 Results and Provides Fiscal Year 2025 Outlook

USANA Exec. Chairman Kevin Guest Invites All to Celebrate March's Listening Awareness Month

Entertainment

USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

AXIL Brands

BellRing Brands

Coty

Big Tree Cloud Holdings Limited - Ordinary Shares

Big Tree Cloud Holdings

Estee Lauder Companies, Inc. (The) Common Stock

Estee Lauder Cos

e.l.f. Beauty

Edgewell Personal Care Company Common Stock

Edgewell Personal Care

FitLife Brands

Herbalife

Honest Co

Interparfums

Kenvue

Lifevantage

Medifast

Nature's Sunshine Products, Inc. - Common Stock

Natures Sunshine Products

Natural Health Trends Corp. - Commn Stock

Natural Health Trends

Nu Skin Enterprises

Olaplex Hldgs

Paranovus Entertainment Technology Ltd. - Class A Ordinary Shares

Paranovus Entertainment

Safety Shot

The Beauty Health Company - Class A Common Stock

Beauty Health

United-Guardian

Unilever

Waldencast

Yatsen Holding Limited American Depositary Shares, each representing twenty (20) Class A Ordinary Shares

Yatsen Holding

DA Davidson

Jefferies

USANA, Inc

Comments

Usana Health Sciences

Notizie

Ultime notizie per Usana Health Sciences (NYSE:USNA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO